Nurix Therapeutics (NRIX) announced that the European Medicines Agency has granted Orphan Drug Designation to bexobrutideg for the treatment of lymphoplasmacytic lymphoma. Bexobrutideg is an orally bioavailable, brain penetrant degrader of Bruton’s tyrosine kinase which is being evaluated in an ongoing Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies, including lymphoplasmacytic lymphoma, also known as Waldenstrom macroglobulinemia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Promising Clinical Data from Nurix Therapeutics’ BTK Degrader NX-5948 Supports Buy Rating
- Nurix Therapeutics management to meet with Oppenheimer
- Promising Developments in Nurix Therapeutics’ BTK Degrader Drive Buy Rating
- Nurix Therapeutics Announces Positive Phase 1 Trial Results
- Nurix Therapeutics presents updated data from ongoing trial of bexobrutideg